ES2170859T3 - Derivados de imidazol 1h-4(5)-sustituidos. - Google Patents

Derivados de imidazol 1h-4(5)-sustituidos.

Info

Publication number
ES2170859T3
ES2170859T3 ES96920543T ES96920543T ES2170859T3 ES 2170859 T3 ES2170859 T3 ES 2170859T3 ES 96920543 T ES96920543 T ES 96920543T ES 96920543 T ES96920543 T ES 96920543T ES 2170859 T3 ES2170859 T3 ES 2170859T3
Authority
ES
Spain
Prior art keywords
sub
present
compounds
describes
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96920543T
Other languages
English (en)
Inventor
James G Phillips
Clark E Tedford
Nishith C Chaturvedi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gliatech Inc
Original Assignee
Gliatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliatech Inc filed Critical Gliatech Inc
Application granted granted Critical
Publication of ES2170859T3 publication Critical patent/ES2170859T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE, COMO ASPECTO PRINCIPAL, COMPUESTOS DE FORMULA GENERAL (1.0) O UNA SAL O HIDRATO FARMACEUTICAMENTE ACEPTABLE DE LOS MISMOS, EN LA CUAL: A ES NHCO SUB,2} CH SUB,3}, NH SUB,2}, NH(CH SUB,3}), N(CH SUB,3}) SUB,2}, OH, OCH SUB,3} O SH; R SUB,2} ES HIDROGENO O UN GRUPO METILO O ETILO; R SUB,3} ES HIDROGENO O UN GRUPO METILO O ETILO; N ES 0, 1, 2, 3, 4, 5 O 6; Y R SUB,1} SE SELECCIONA ENTRE EL GRUPO FORMADO POR (A) CICLOALQUILO C SUB,3} A C SUB,8}; (B) FENILO O FENILO SUSTITUIDO; (D) HETEROCICLILO; (E) DECAHIDRONAFTALENO Y (F) OCTAHIDROINDENO; O R SUB,1} Y X PUEDEN TOMARSE CONJUNTAMENTE PARA INDICAR UNA ESTRUCTURA DE ANILLO BICICLICA 5,6 O 6,6 SATURADA CUANDO X ES NH, O O S. TAMBIEN SE CONTEMPLA QUE LOS ESTEREOISOMEROS INDIVIDUALES DE LOS COMPUESTOS DE FORMULA ESTRUCTURAL (1.0) ANTERIOR, ASI COMO LAS MEZCLAS DE LOS MISMOS, SE ENCUENTRAN DENTRO DEL ALCANCE DE LA PRESENTE INVENCION. LOS COMPUESTOS DE LA PRESENTE INVENCION PRESENTAN ACTIVIDAD ANTAGONISTA DEL RECEPTOR DE HISTAMINA H SUB,3}. ESTA INVENCION TAMBIEN DESCRIBE COMPOSICIONES FARMACEUTICAS QUE INCLUYEN UN VEHICULO FARMACEUTICAMENTE ACEPTABLE JUNTO CON UNA CANTIDAD EFICAZ DE UN COMPUESTO DE FORMULA 1.0. LA PRESENTE INVENCION TAMBIEN DESCRIBE UN PROCEDIMIENTO PARA TRATAR TRASTORNOS EN LOS CUALES EL ANTAGONISMO DE LOS RECEPTORES H SUB,3}DE HISTAMINA PUEDE PRESENTAR IMPORTANCIA TERAPEUTICA.
ES96920543T 1995-05-30 1996-05-29 Derivados de imidazol 1h-4(5)-sustituidos. Expired - Lifetime ES2170859T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US45452295A 1995-05-30 1995-05-30

Publications (1)

Publication Number Publication Date
ES2170859T3 true ES2170859T3 (es) 2002-08-16

Family

ID=23804951

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96920543T Expired - Lifetime ES2170859T3 (es) 1995-05-30 1996-05-29 Derivados de imidazol 1h-4(5)-sustituidos.

Country Status (16)

Country Link
US (1) US6166060A (es)
EP (1) EP0841922B1 (es)
JP (1) JPH11506106A (es)
KR (1) KR19990022136A (es)
CN (1) CN1192144A (es)
AT (1) ATE213412T1 (es)
AU (1) AU721325B2 (es)
CA (1) CA2222099A1 (es)
DE (1) DE69619381T2 (es)
DK (1) DK0841922T3 (es)
ES (1) ES2170859T3 (es)
FI (1) FI974364A7 (es)
NO (1) NO975483D0 (es)
NZ (1) NZ308931A (es)
PT (1) PT841922E (es)
WO (1) WO1996038142A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932590A (en) * 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9715814D0 (en) 1997-07-25 1997-10-01 Black James Foundation Histamine H3 receptor ligands
GB2344588B (en) * 1997-07-25 2001-11-14 Black James Foundation 1H-4(5)-substituted imidazole derivatives their preparation and their use as histamine H 3 receptor ligands
WO2000042023A1 (en) 1999-01-18 2000-07-20 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
US6437147B1 (en) 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6610721B2 (en) 2000-03-17 2003-08-26 Novo Nordisk A/S Imidazo heterocyclic compounds
WO2002013821A1 (en) 2000-08-17 2002-02-21 Gliatech, Inc. Novel alicyclic imidazoles as h3 agents
FR2827863A1 (fr) * 2001-07-27 2003-01-31 Sanofi Synthelabo Derives d'aminoalkylimidazole, leur preparation et leur utilisation en therapeutique
BR0308118A (pt) * 2002-03-01 2005-01-11 Warner Lambert Co Método para o tratamento de osteoartrite
CN1784220B (zh) * 2003-05-05 2011-08-03 前体生物药物股份公司 谷氨酰胺酰基和谷氨酸环化酶效应物的应用
AU2004290499C1 (en) * 2003-11-03 2011-02-24 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1720861A2 (en) 2004-02-25 2006-11-15 Eli Lilly And Company Histamine h3 receptor antagonists, preparation and therapeutic uses
BRPI0509298A (pt) 2004-04-01 2007-09-18 Lilly Co Eli composto, composição farmacêutica, métodos de inibir receptor h3 de histamina em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, obesidade, e um distúrbio ou doença, e, uso de um composto
EP1756051B1 (en) * 2004-06-02 2012-09-12 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
CN101006082B (zh) 2004-08-23 2010-09-29 伊莱利利公司 组胺h3受体药剂、制备方法和治疗用途
JP5057982B2 (ja) 2004-10-18 2012-10-24 イーライ リリー アンド カンパニー ヒスタミンｈ３受容体阻害剤、製造及び治療的使用
EP1816912A4 (en) * 2004-11-23 2008-09-10 Merck & Co Inc TREATMENT OF APOPLEXY WITH INVERSE HISTAMINE H3 AGONISTS OR HISTAMINE H3 ANTAGONISTS
BRPI0608523A2 (pt) * 2005-03-17 2010-11-16 Lilly Co Eli composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos para inibir receptor de histamina h3 em um mamìfero, para tratar ou prevenir um distúrbio do sistema nervoso, para tratar ou prevenir obesidade e para tratar ou prevenir um distúrbio ou doença, e, uso de um composto ou um sal do mesmo
EP1707203A1 (en) 2005-04-01 2006-10-04 Bioprojet Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands
AU2006232871B9 (en) 2005-04-01 2011-11-24 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
EP1717233A1 (en) 2005-04-29 2006-11-02 Bioprojet Histamine H3-receptor ligands and their therapeutic application
EP1717235A3 (en) 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
WO2007063385A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
WO2008104942A2 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
JP7048572B6 (ja) * 2016-09-16 2023-12-20 リサーチ トライアングル インスティテュート テトラヒドロイソキノリンカッパーオピオイドアンタゴニスト

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2069481B (en) * 1980-02-13 1983-07-27 Farmos Oy Substituted imidazole derivatives
GB2110663B (en) * 1981-12-04 1985-08-07 Farmos Group Ltd Imidazole derivatives
FR2579596B1 (fr) * 1985-03-26 1987-11-20 Inst Nat Sante Rech Med (imidazolyl-4) piperidines, leur preparation et leur application en therapeutique
NL8601585A (nl) * 1986-06-19 1988-01-18 Vereniging Voor Christelijk Wetenschappelijk Onderwijs N-(2-gesubstitueerde alkyl)-n-imidazol-4-yl alkyl guanidine.
US4996221A (en) * 1987-01-13 1991-02-26 The Board Of Trustees Of The Leland Stanford Junior University Histamine derivatives as immune modulators
IL92441A (en) * 1988-12-07 1993-05-13 Tanabe Seiyaku Co Imidazole containing peptides, their preparation and pharmaceutical compositions containing them
US5248689A (en) * 1989-11-06 1993-09-28 Smithkline Beecham Corporation Substituted N-(imidazolyl)alkyl alanine derivatives
FR2669030B1 (fr) * 1990-11-14 1992-12-31 Adir Nouveaux derives d'imidazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2671083B1 (fr) * 1990-12-31 1994-12-23 Inst Nat Sante Rech Med Nouvelles 4-(4-imidazolyl) piperidines substituees en 1, leur preparation ainsi que leurs applications therapeutiques.
JPH06505265A (ja) * 1991-02-27 1994-06-16 シード・キャピタル・インベストメント・（エス・シー・アイ）・ベスローテン・フェンノートシャップ ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体
FR2686084B1 (fr) * 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
US5217986A (en) * 1992-03-26 1993-06-08 Harbor Branch Oceanographic Institution, Inc. Anti-allergy agent
FR2711990B1 (fr) * 1993-11-05 1995-12-08 Exsymol Sa Produit pseudodipeptide possédant un groupement imidazole, et applications thérapeutiques, cosmétologiques et agroalimentaires.
FR2732017B1 (fr) * 1995-03-21 2000-09-22 Inst Nat Sante Rech Med Nouveaux derives de l'imidazole antagonistes et/ou agonistes du recepteur h3 de l'histamine, leur preparation et leurs applications therapeutiques

Also Published As

Publication number Publication date
JPH11506106A (ja) 1999-06-02
DE69619381D1 (de) 2002-03-28
MX9709210A (es) 1998-07-31
AU721325B2 (en) 2000-06-29
KR19990022136A (ko) 1999-03-25
AU5881796A (en) 1996-12-18
US6166060A (en) 2000-12-26
NZ308931A (en) 2001-10-26
NO975483D0 (no) 1997-11-28
ATE213412T1 (de) 2002-03-15
CN1192144A (zh) 1998-09-02
CA2222099A1 (en) 1996-12-05
EP0841922B1 (en) 2002-02-20
FI974364A0 (fi) 1997-11-28
EP0841922A4 (en) 1999-03-10
FI974364A7 (fi) 1997-11-28
PT841922E (pt) 2002-07-31
WO1996038142A1 (en) 1996-12-05
EP0841922A1 (en) 1998-05-20
DK0841922T3 (da) 2002-06-03
DE69619381T2 (de) 2002-11-21

Similar Documents

Publication Publication Date Title
ES2170859T3 (es) Derivados de imidazol 1h-4(5)-sustituidos.
ES2163019T3 (es) Derivados de 2-(1h-4(5)-imidazolil)ciclopropilo.
CR9910A (es) Antagonistas del receptor 3 de la histamina
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
ES2194844T3 (es) Antagonistas del receptor de aminoacidos excitadores.
PA8547901A1 (es) Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6
RU94044671A (ru) Применение непептидных антагонистов рецептора тахикинина
AR008577A1 (es) Pirazolopirimidinas, una composicion que las comprende, un procedimiento para preparar dicha composicion, un procedimiento para su preparacion,compuestos intermediarios de las mismas y un procedimiento para su preparacion
AP2001002307A0 (en) B3 adrenergic receptor agonists and uses thereof.
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
PL361361A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
SE9904508D0 (sv) New compounds
AR029373A1 (es) Metodo para el tratamiento de migranas, utilizando compuestos antagonistas selectivos de los receptores iglur5, uso de dichos compuestos antagonistas selectivos en la manufactura de medicamentos para el tratamiento de migranas y dichos compuestos antagonistas
PL361282A1 (en) Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
YU53100A (sh) Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora
IT1250049B (it) Composti triciclici.
MX2026000537A (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
UY26919A1 (es) Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1
ES2159345T3 (es) Indazolcarboxamidas.
PA8540601A1 (es) Derivados de alcoxicarbonilaminotetrazolil fenilo o acido alcoxicarbonilamino benzoico como antagonistas ip
AR042444A1 (es) Metodo para el tratamiento de desordenes del movimiento mediante la utilizacion de acido barbiturico
ES2093246T3 (es) Compuestos de benzazepina terapeuticos.
ATE302184T1 (de) Phenoxyalkylaminderivate als agonisten des opioid-delta rezeptors
BRPI0410127A (pt) derivados de pirimidina substituìdos
ATE410168T1 (de) A1 adenosin-rezeptor-antagonisten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 841922

Country of ref document: ES